Sintilimab，Surufatinib
PreclinicalSmall molecule
Sintilimab，Surufatinib is one of 25 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Neuroendocrine Carcinoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Eloxatin
TevaApproved
Kyprolis
VVirionyx Corporation Limited
Approved
Sandostatin
Sun PharmaApproved
Tarlatamab-Dznl
AmgenPhase 3
Imfinzi
AstraZenecaPhase 2
Tecentriq
RochePhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sintilimab，Surufatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details